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j ourna l homepage: www.eb iomed ic ine.comEditorialRNA-Targeting Therapies: Translating HopeOn July 20, 2016, the UK health regulator NICE published ﬁnal guid- excitement for read-through therapies in some camps. An alternative ap-
ance recommending the drug ataluren for children with Duchenne mus-
cular dystrophy (DMD). This was a momentous announcement for those
who had campaigned vociferously for its approval in the UK. DMD is a
rare X-linked disorder that causes progressive muscular weakness. Most
boys are wheelchair dependent by their early teens, and face life-
threatening lung and heart complications in their 20s. DMD is usually
fatal by the age of 30 years. There is no curative therapy to date; therefore
there is an urgent need to develop effective targeted therapies.
Ataluren, approved by the EMA since August 2014, is expected to ben-
eﬁt 10–15% of boys suffering from the nonsensemutation formof the dis-
ease (nmDMD). Nonsense mutations are single nucleotide variants
within the coding sequence of a gene that encodes an in-frame stop
codon. Premature termination codons (PTCs) lead to short, unstable
mRNA transcripts that can be degraded. Any mRNA that is transcribed
will produce truncated, non-functional proteins. In the case of nmDMD,
reduced levels of aberrant dystrophin make muscle ﬁbers vulnerable to
damage. Ataluren is an example of a read-through therapeutic – a chem-
ical that selectively induces ribosomal read-through of premature, but not
normal, termination codons in themRNA. This results in the formation of
stabilized mRNA and full-length, functional protein. The rationale is that
although the levels of corrected functional protein are generally low due
to the inability to target everymuscle ﬁber, there may be enough present
to alleviate the consequences of the pathology. Crucially, Phase III clinical
results indicated that none of the children in the treatment group lost am-
bulation during the 48-week trial, compared to 8% treated with placebo
(0 out of 47 compared to 4 of 52, NCT01826487). This demonstrated
the ability of ataluren to delay loss of walking in children with nmDMD,
and solidiﬁed the EMA’s decision for European approval.
Read-through therapies were ﬁrst described in the late 1970s when
aminoglycoside antibiotics were shown to bind bacterial ribosomes and
allow the insertion of amino acids at PTCs, enabling translational read-
through. As 10% of inherited diseases are caused by PTC mutations,
and many cancers acquire PTC mutations during their evolution, the
clinical potential for using read-through therapies to treat multiple dis-
eases is clear. In spite of promising results in cell culture, aminoglyco-
sides in vivo cause nephrotoxicity and irreversible damage to cochlea
hair cells. High-throughput screening approaches were undertaken by
pharmaceutical and academic enterprises to identify drugs possessing
read-through promoting behavior without the associated toxicity.
Ataluren demonstrated translational read-through performance, low
toxicity and could be delivered orally, catapulting it to lead-compound
status. Ataluren is currently being tested in a number of indications in-
cluding a Phase III clinical trial in patientswithnonsensemutation cystic
ﬁbrosis (NCT02369731), and Phase II trials in patients with nonsense
mutation aniridia (NCT02647359) and nonsense mutation Dravet syn-
drome or cyclin-dependent kinase-like 5 deﬁciency (NCT02758626).
Despite a number of favorable clinical results, a paucity of full mecha-
nistic understanding and questionable clinical efﬁcacy has dampenedhttp://dx.doi.org/10.1016/j.ebiom.2016.10.011
2352-3964/© 2016 The Author. Published by Elsevier B.V. This is an open access article underproach to correct genetic mutations by targeting RNA is to utilize the nat-
ural process of exon skipping. Exon-skipping therapies (ESTs) co-opt the
natural process of pre-mRNA splicing that remove introns to leave
protein-encoding exons. ESTs consist of an antisense oligonucleotide
(AON) that binds to the mutated exon enabling translational machinery
to skip over faulty sections of pre-mRNA. The mature mRNA comprises
fewer exons, but a restored reading frame, enabling productionof a slight-
ly shorter protein. This innovative therapy does have caveats. The resul-
tant protein must retain sufﬁcient functionality to be able to overcome
the pathology. Furthermore, intracellular delivery of AONs is a huge chal-
lengewithmuch research being spent in formulating conjugates that im-
prove half-life and cell speciﬁcity. Nevertheless, the potential for broad
clinical utility is reﬂected by a growing drug development pipeline to
treat a range of disorders including DMD and neurogenetic diseases.
On September 19, 2016, the FDA controversially approved the EST
eteplirsen for the treatment of DMD. Eteplirsen acts by skipping over
exon 51 to produce a largely functional dystrophin protein – a strategy
amenable to approximately 13% of DMD patients. The crux of this con-
troversy was based on internal conﬂict at the FDA as to whether the
modest increase in dystrophin levels, induced by eteplirsen, were clini-
cally meaningful. The FDA Advisory Committee felt that ﬂaws in the de-
sign and conduct of the available clinical trials were unable to provide
reasonable evidence, and voted against approval in April 2016. Howev-
er, the Director of the Center for Drug Evaluation and Research
overruled this decision, recommending approval of eteplirsen under
the accelerated approval pathway restricted to treat serious conditions.
This decision exposed an awkward question: how much compromise
should be made to accelerate approval of a potentially beneﬁcial but
clinically unproven drug? As such, the FDA has insisted that more clin-
ical datamust be obtained to demonstrate etepliren’s efﬁcacy. If no ben-
eﬁt is found, FDA approval could be withdrawn.
Both read-through therapies and ESTs use innovative strategies to
target RNA and correct disease-causing mutations. However, research
and development of promising compounds is extraordinarily expensive
and costs must be recovered during product commercialization. Using
ataluren as an example, treating a single child with nmDMD in the UK
will cost £220,000 per year. Healthcare systems have to weigh up the
potential gains of a drug’s long-term beneﬁts with available funds.
Well-conducted and adequately powered trials are crucial to generate
meaningful data to assess clinical beneﬁt of a new drug and facilitate
regulatory approval. Translational research can be a slow and expensive
process but will ultimately reduce the number of ineffective drugs that
are brought tomarket. Life-limiting diseases like DMDdesperately need
innovative treatment strategies, and drugs that correct RNA translation
may be part of the answer.
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